Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 4
2019 12
2020 3
2021 2
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Epidemiology of Renal Cell Carcinoma.
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P. Capitanio U, et al. Eur Urol. 2019 Jan;75(1):74-84. doi: 10.1016/j.eururo.2018.08.036. Epub 2018 Sep 19. Eur Urol. 2019. PMID: 30243799 Free PMC article. Review.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
METHODS: We did a multicentre, open-label, randomised, controlled, phase 3 trial in 139 sites (137 hospitals and two clinics). Eligible patients were women aged 20-75 years with histologically diagnosed stage I to IIIB invasive breast cancer (intermediate to high risk of r …
METHODS: We did a multicentre, open-label, randomised, controlled, phase 3 trial in 139 sites (137 hospitals and two clinics). Eligible pati …
MGMT promoter methylation in 1p19q-intact gliomas.
Kinslow C, Siegelin MD, Iwamoto FM, Gallitto M, Neugut AI, Yu JB, Cheng SK, Wang TJC. Kinslow C, et al. Res Sq [Preprint]. 2023 Oct 6:rs.3.rs-3393238. doi: 10.21203/rs.3.rs-3393238/v1. Res Sq. 2023. PMID: 37886555 Free PMC article. Updated. Preprint.
Given that the prognostic and predictive role of MGMT status for grade 2-3 gliomas is unresolved, we determined the effect of MGMT status on OS in patients with 1p19q-intact gliomas in the National Cancer Database (NCDB). METHODS: We queried the NCDB from 2018-2019 for pat …
Given that the prognostic and predictive role of MGMT status for grade 2-3 gliomas is unresolved, we determined the effect of MGMT status on …
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE).
Pergola PE, Davidson M, Jensen C, Mohseni Zonoozi AA, Raj DS, Andreas Schytz P, Tuttle KR, Perkovic V. Pergola PE, et al. J Am Soc Nephrol. 2024 Jan 1;35(1):74-84. doi: 10.1681/ASN.0000000000000245. Epub 2023 Dec 13. J Am Soc Nephrol. 2024. PMID: 38088558 Clinical Trial.
RESULTS: The trial was terminated early due to the coronavirus disease 2019 pandemic, and thus, data up to week 12 are presented. Hb levels significantly increased from baseline to week 12 with ziltivekimab 7.5, 15, and 30 mg (treatment differences versus placebo: +0.57 g/ …
RESULTS: The trial was terminated early due to the coronavirus disease 2019 pandemic, and thus, data up to week 12 are presented. Hb …
MGMT promoter methylation in 1p19q-intact gliomas.
Kinslow CJ, Siegelin MD, Iwamoto FM, Gallitto M, Neugut AI, Yu JB, Cheng SK, Wang TJC. Kinslow CJ, et al. J Neurooncol. 2024 Jan;166(1):73-78. doi: 10.1007/s11060-023-04515-z. Epub 2023 Dec 20. J Neurooncol. 2024. PMID: 38114801
Given that the prognostic and predictive role of MGMT status for grade 2-3 gliomas is unresolved, we determined the effect of MGMT status on OS in patients with 1p19q-intact gliomas in the National Cancer Database (NCDB). METHODS: We queried the NCDB from 2018 to 2019 for …
Given that the prognostic and predictive role of MGMT status for grade 2-3 gliomas is unresolved, we determined the effect of MGMT status on …
Spatial distribution, determinants and trends of full vaccination coverage in children aged 12-59 months in Peru: A subanalysis of the Peruvian Demographic and Health Survey.
Al-Kassab-Córdova A, Silva-Perez C, Maguiña JL. Al-Kassab-Córdova A, et al. BMJ Open. 2022 Nov 11;12(11):e050211. doi: 10.1136/bmjopen-2021-050211. BMJ Open. 2022. PMID: 36368757 Free PMC article.
OBJECTIVE: To assess the spatial distribution, trends and determinants of crude full vaccination coverage (FVC) in children aged 12-59 months between 2010 and 2019 in Peru. DESIGN, SETTING AND ANALYSIS: A cross-sectional study based on the secondary data analysis of the 20 …
OBJECTIVE: To assess the spatial distribution, trends and determinants of crude full vaccination coverage (FVC) in children aged 12-59 month …
Neutropenia in Barth syndrome: characteristics, risks, and management.
Steward CG, Groves SJ, Taylor CT, Maisenbacher MK, Versluys B, Newbury-Ecob RA, Ozsahin H, Damin MK, Bowen VM, McCurdy KR, Mackey MC, Bolyard AA, Dale DC. Steward CG, et al. Curr Opin Hematol. 2019 Jan;26(1):6-15. doi: 10.1097/MOH.0000000000000472. Curr Opin Hematol. 2019. PMID: 30451719 Free PMC article. Clinical Trial.
RECENT FINDINGS: In 88 patients with BTHS, neutropenia, that is, at least one count below 1.5 10/l, was detected in 74 (84%) and 44% had severe chronic neutropenia, with multiple counts below 0.5 10/l. ...Monocytosis, that is, monocytes more than 1.0 10/l, was obser …
RECENT FINDINGS: In 88 patients with BTHS, neutropenia, that is, at least one count below 1.5 10/l, was detected in 74 (84%) a …
Advance care plans and hospitalized frail older adults: a systematic review.
Hopkins SA, Bentley A, Phillips V, Barclay S. Hopkins SA, et al. BMJ Support Palliat Care. 2020 Jun;10(2):164-174. doi: 10.1136/bmjspcare-2019-002093. Epub 2020 Apr 2. BMJ Support Palliat Care. 2020. PMID: 32241957 Free PMC article.
Electronic search of MEDLINE, CINAHL, ASSIA, PsycINFO and Embase databases from January 1990 to May 2019 inclusive. Studies in the acute setting of populations with a mean age >75 years, not focused on a disease-specific terminal condition were included. ...One r …
Electronic search of MEDLINE, CINAHL, ASSIA, PsycINFO and Embase databases from January 1990 to May 2019 inclusive. Studies in the ac …
Multiscale spatial gradient features for 18F-FDG PET image-guided diagnosis of Alzheimer's disease.
Pan X, Adel M, Fossati C, Gaidon T, Wojak J, Guedj E; Alzheimer’s Disease Neuroimaging Initiative. Pan X, et al. Comput Methods Programs Biomed. 2019 Oct;180:105027. doi: 10.1016/j.cmpb.2019.105027. Epub 2019 Aug 12. Comput Methods Programs Biomed. 2019. PMID: 31430595
NC with an accuracy, a sensitivity and a specificity values of 93.65%, 91.22% and 96.25%, respectively. For the case of pMCI vs. sMCI, the three metrics are 75.38%, 74.84% and 77.11%, which is significantly better than most existing methods. ...
NC with an accuracy, a sensitivity and a specificity values of 93.65%, 91.22% and 96.25%, respectively. For the case of pMCI vs. sMCI, the t …
20 results